WSJ
22 Jun 2026, 11:42 UTC · 2h ago
AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
WSJ
22 Jun 2026, 11:42 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
AbbVie has agreed to acquire Apogee Therapeutics for approximately $10.9 billion in cash. — A multi-billion dollar acquisition signals aggressive expansion and high valuation for the target's assets, typically boosting the target's stock and signaling confidence in the sector.
+0.60The acquisition is intended to strengthen AbbVie's immunology and inflammation portfolio. — Diversifying and strengthening a core therapeutic pipeline reduces long-term revenue risk from patent cliffs.
+0.30Which stocks this story touches
The company is being acquired for approximately $10.9 billion in cash.
Continue reading
6 related stories
Search tags
The company is expanding its immunology and inflammation portfolio through a strategic acquisition.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
PRNewsWire
1h ago
